Home » Stocks » Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. (AGIO)

Stock Price: $40.55 USD -0.53 (-1.29%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $41.44 +0.89 (2.20%) Aug 14, 6:46 PM

Stock Price Chart

Key Info

Market Cap 2.80B
Revenue (ttm) 185.91M
Net Income (ttm) -339.26M
Shares Out 69.11M
EPS (ttm) -5.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $40.55
Previous Close $41.08
Change ($) -0.53
Change (%) -1.29%
Day's Open 41.03
Day's Range 40.38 - 41.38
Day's Volume 432,982
52-Week Range 27.77 - 56.75

More Stats

Market Cap 2.80B
Enterprise Value 2.37B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 69.11M
Float 61.26M
EPS (basic) -5.3
EPS (diluted) -5.21
FCF / Share -5.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.46M
Short Ratio 11.41
Short % of Float 13.86%
Beta 2.03
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 15.07
PB Ratio 4.99
Revenue 185.91M
Operating Income -348.38M
Net Income -339.26M
Free Cash Flow -369.91M
Net Cash 429.82M
Net Cash / Share 6.22
Gross Margin -158.30%
Operating Margin -187.39%
Profit Margin -182.50%
FCF Margin -198.97%
ROA -24.74%
ROE -62.18%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (14)

Buy 11
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(64.81% upside)
Current: $40.55
Target: 66.83
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth24.92%119.45%-38.46%18.22%-9.55%155.82%1.76%14.97%-
Gross Profit11792.9943.0169.8959.1265.3625.5525.1121.84
Operating Income-426-362-321-201-119-54.13-38.88-23.00-16.63
Net Income-411-346-315-198-118-53.50-39.41-20.10-23.71
Shares Outstanding59.9957.4246.5939.1337.4333.6715.423.403.01
Earnings Per Share-6.86-6.03-6.75-5.07-3.15-1.59-2.83-8.02-8.90
Operating Cash Flow-371-304-28538.56-76.95-59.35-56.40-49.55-15.22
Capital Expenditures-12.17-6.99-4.63-9.92-20.16-2.22-1.29-1.48-1.91
Free Cash Flow-383-311-29028.65-97.11-61.57-57.69-51.02-17.13
Cash & Equivalents565585424541317342167129180
Total Debt114--------
Net Cash / Debt451585424541317342167129180
Book Value641688376359345424131-72.02-52.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Agios Pharmaceuticals, Inc.
Country United States
Employees 536
CEO Jacqualyn A. Fouse

Stock Information

Ticker Symbol AGIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AGIO
IPO Date July 24, 2013


Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.